People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology, Medical Devices, Other Health Care, Other Technology, Pharmaceuticals, Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arcellx, Inc. | — | Biotechnology | Series D+ | $272.8M | $1.8B | 2019 |
| Tune Therapeutics, Inc. | — | Biotechnology | Series D+ | $182.4M | $3.1B | 2023 |
| Minerva Surgical Inc | — | Medical Devices | Series B | $167.3M | $397.4M | 2011 |
| Genocea Biosciences, Inc. | — | Biotechnology | Series C | $153.6M | $3.0B | 2019 |
| Monte Rosa Therapeutics, Inc. | — | Biotechnology | Series C | $143.0M | $3.0B | 2020 |
| SpyGlassPharma, Inc. | — | Other Health Care | Series C | $134.8M | $484.8M | 2019 |
| Adaptimmune Ltd | — | Biotechnology | Series D+ | $103.8M | $4.3B | 2014 |
| Ivantis, Inc. | — | Other Technology | Series C | $101.1M | $785.7M | 2014 |
| 858 Therapeutics, Inc. | — | Pharmaceuticals | Series B | $65.2M | $177.0M | 2024 |
| Nexo Therapeutics, Inc. | — | Biotechnology | Series C | $60.0M | $993.8M | 2022 |
| Cardionomic, Inc. | — | Other Health Care | Series B | $51.7M | $76.2M | 2015 |
| Rotation Medical Inc | — | Other Health Care | Series B | $51.1M | $177.2M | 2014 |
| Nkarta, Inc. | — | Biotechnology | Series C | $43.9M | $1.8B | 2019 |
| CRISPR Therapeutics AG | — | Biotech | Series B | $36.0M | $39.7M | 2020 |
| Oculeve, Inc. | — | Other Health Care | Series B | $33.2M | $368.9M | 2012 |
| FirstLight Bio, Inc. | — | Biotechnology | Series B | $25.4M | $475.0M | 2022 |
| Launchpad Therapeutics, Inc. | — | Biotechnology | Series A | $10.0M | $111.4M | 2022 |
Ali Behbahani at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ali Behbahani on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Nehra | 3 | 11 |
| Tara Butler | 2 | 12 |
| BRADLEY BOLZON | 2 | 10 |
| Tiba Aynechi | 2 | 9 |
| Fouad Azzam | 2 | 8 |
| Simeon George | 2 | 8 |
| Carlo Rizzuto | 2 | 7 |
| Alexander Mayweg | 2 | 4 |
| Jill Carroll | 2 | 4 |
| Michael DeMane | 2 | 4 |
| Albert Graf | 2 | 2 |
| Robert Anderson | 1 | 24 |
| Asish Xavier | 1 | 18 |
| Peter Thompson | 1 | 16 |
| Kevin Bitterman | 1 | 15 |
| LEON CHEN | 1 | 15 |
| Michael Kim | 1 | 14 |
| Kirk Nielsen | 1 | 13 |
| Brook Byers | 1 | 13 |
| Bruce Feuchter | 1 | 12 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.